Drug intelligence / Profile preview

RC0615

Development stage: Preclinical
Lead developer: Nanjing RegeneCore Biotech

Overview

RC0615 is a preclinical-stage therapeutic candidate being developed by Nanjing Regenecore Biotech (also known as Nanjing Chongyuan Biotechnology) for the treatment of autoimmune diseases. As of 2024, the specific molecular target and modality of RC0615 have not been publicly disclosed by the developer. The program is part of Regenecore's research and development pipeline, which focuses on innovative therapies for immunological and regenerative medicine applications. The asset is currently in the early stages of development, with its pharmacological profile and mechanism of action remaining proprietary.

Beyond the preview

Go deeper on RC0615.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RC0615.

Explore the full profile